View Financial HealthHelix BioPharma 배당 및 자사주 매입배당 기준 점검 0/6Helix BioPharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-1.4%자사주 매입 수익률총 주주 수익률-1.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Nov 24Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026.공시 • Aug 23Helix BioPharma Corp. announced that it has received CAD 1.66675 million in fundingHelix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders.공시 • May 21Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million.Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction. Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG.공시 • May 15Helix BioPharma Corp. announced that it expects to receive CAD 13 million in fundingHelix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025.공시 • Mar 13Helix BioPharma Corp. Announces Executive AppointmentsHelix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market.공시 • Jan 10Helix BioPharma Corp. announced that it has received CAD 3 million in fundingHelix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder.공시 • Dec 18Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025.공시 • Apr 09Helix BioPharma Corp. announced that it has received CAD 1.915 million in fundingOn April 8, 2024, Helix BioPharma Corp. closed the transaction. The Offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on August 9, 2024 in accordance with applicable securities laws. In connection with the closing. The company paid a cash fee of 10% of gross proceeds equal to CAD 191,500.005 raised to an eligible finder.공시 • Mar 30Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in fundingHelix BioPharma Corp announced private placement financing of 12,766,667 common shares of the company at a price of CAD 0.15 per common share for gross proceeds of CAD 1,915,000 on March 28, 2024. The Offering is subject to customary closing conditions including the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange. In connection with the closing, the Company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. The Common Shares will be subject to a hold period of four months and one day from the closing date in accordance with applicable securities laws.공시 • Feb 14+ 1 more updateHelix BioPharma Corp. Appoints Praveen Varshney as Chief Financial OfficerHelix BioPharma Corp. announced that Mr. Praveen Varshney has been appointed as Chief Financial Officer (CFO) and Corporate Secretary. Mr. Praveen Varshney has been a principal of Varshney Capital Corp. since 1991. He's also a Founding Director of Pyfera Growth Capital &a Founding Director of Humanitas Smart Planet Fund, both with a social impact focus. Mr. Varshney obtained his UBC Sauder B Comm in 1987 and is a FCPA, FCA. He has been a member of the Vancouver Chapter of EO since 1996 and a founding Director &Charter Member of the Vancouver since 2000. He has been a Co-Founder, Director or Officer of many publicly traded and private companies over the years including Mogo Inc. and Little Kitchen Academy. He"s also on three charity boards such as The Vancouver Foundation and Foundations for Social Change.공시 • Nov 08Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024.공시 • Oct 13Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsHelix BioPharma Corp. announced that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023. During the conference, Helix will highlight the enhanced effects of anti-PD1 immunotherapy when combined with L-DOS47 in an orthotopic Pancreatic tumor model in mice. The drug has already been administered to over 120 patients in the clinic across 4 clinical trials and has been shown to be safe and well tolerated. Additionally, L-DOS47 has also demonstrated promising anti-tumor activity across a range of doses, both as monotherapy and in combination with chemotherapy agents. The Company is open to collaborating with the right partner(s) to explore potential synergies with anti-PD1 and other treatment regimens. Poster Presentation Details: Title: Neutralizing Acidosis with ADC L-DOS47 Urease Immunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in A Preclinical Orthotopic Model of Pancreatic Adenocarcinoma. Abstract Number: 35494. Poster Presentation Date and Time: October 13, 12:30 pm - 4:00 pm. Location: Level 2, Exhibit Hall D. Poster Session B, Poster Number: B125.공시 • Aug 24Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in fundingHelix BioPharma Corp. announced a private placement financing of 16,655,557 common shares at a price of CAD 0.18 per common share for proceeds of CAD 2,998,000 on August 22, 2023. The common shares issued pursuant are subject to a statutory hold period of four months. Helix BioPharma Corp. announces that it has closed the first tranche of private placement financing for gross proceeds of CAD 2,998,000.공시 • Aug 23Helix BioPharma Corp. Announces Executive ChangesHelix BioPharma Corp. announced appointment of Mr. Janusz Grabski to the board of directors of the Company with an immediate effect. Mr. Grabski is a lawyer specialized in corporate law and real estate law with over twenty years of experience. Mr. Grabski is based in Warsaw, Poland. Alongside the appointment, the Company also announced resignation of Mr. Christopher Maciejewski from the board of directors of the Company due to personal reasons.공시 • Nov 18Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 HBPC.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: HBPC.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Helix BioPharma 배당 수익률 vs 시장HBPC.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (HBPC.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.4%분석가 예측 (HBPC.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 HBPC.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 HBPC.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 HBPC.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: HBPC.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 09:48종가2026/05/18 00:00수익2026/01/31연간 수익2025/07/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Helix BioPharma Corp.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ahu DemirNOBLE Capital Markets, Inc.
공시 • Nov 24Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026.
공시 • Aug 23Helix BioPharma Corp. announced that it has received CAD 1.66675 million in fundingHelix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders.
공시 • May 21Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million.Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction. Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG.
공시 • May 15Helix BioPharma Corp. announced that it expects to receive CAD 13 million in fundingHelix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025.
공시 • Mar 13Helix BioPharma Corp. Announces Executive AppointmentsHelix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market.
공시 • Jan 10Helix BioPharma Corp. announced that it has received CAD 3 million in fundingHelix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder.
공시 • Dec 18Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025.
공시 • Apr 09Helix BioPharma Corp. announced that it has received CAD 1.915 million in fundingOn April 8, 2024, Helix BioPharma Corp. closed the transaction. The Offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on August 9, 2024 in accordance with applicable securities laws. In connection with the closing. The company paid a cash fee of 10% of gross proceeds equal to CAD 191,500.005 raised to an eligible finder.
공시 • Mar 30Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in fundingHelix BioPharma Corp announced private placement financing of 12,766,667 common shares of the company at a price of CAD 0.15 per common share for gross proceeds of CAD 1,915,000 on March 28, 2024. The Offering is subject to customary closing conditions including the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange. In connection with the closing, the Company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. The Common Shares will be subject to a hold period of four months and one day from the closing date in accordance with applicable securities laws.
공시 • Feb 14+ 1 more updateHelix BioPharma Corp. Appoints Praveen Varshney as Chief Financial OfficerHelix BioPharma Corp. announced that Mr. Praveen Varshney has been appointed as Chief Financial Officer (CFO) and Corporate Secretary. Mr. Praveen Varshney has been a principal of Varshney Capital Corp. since 1991. He's also a Founding Director of Pyfera Growth Capital &a Founding Director of Humanitas Smart Planet Fund, both with a social impact focus. Mr. Varshney obtained his UBC Sauder B Comm in 1987 and is a FCPA, FCA. He has been a member of the Vancouver Chapter of EO since 1996 and a founding Director &Charter Member of the Vancouver since 2000. He has been a Co-Founder, Director or Officer of many publicly traded and private companies over the years including Mogo Inc. and Little Kitchen Academy. He"s also on three charity boards such as The Vancouver Foundation and Foundations for Social Change.
공시 • Nov 08Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024.
공시 • Oct 13Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsHelix BioPharma Corp. announced that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023. During the conference, Helix will highlight the enhanced effects of anti-PD1 immunotherapy when combined with L-DOS47 in an orthotopic Pancreatic tumor model in mice. The drug has already been administered to over 120 patients in the clinic across 4 clinical trials and has been shown to be safe and well tolerated. Additionally, L-DOS47 has also demonstrated promising anti-tumor activity across a range of doses, both as monotherapy and in combination with chemotherapy agents. The Company is open to collaborating with the right partner(s) to explore potential synergies with anti-PD1 and other treatment regimens. Poster Presentation Details: Title: Neutralizing Acidosis with ADC L-DOS47 Urease Immunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in A Preclinical Orthotopic Model of Pancreatic Adenocarcinoma. Abstract Number: 35494. Poster Presentation Date and Time: October 13, 12:30 pm - 4:00 pm. Location: Level 2, Exhibit Hall D. Poster Session B, Poster Number: B125.
공시 • Aug 24Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in fundingHelix BioPharma Corp. announced a private placement financing of 16,655,557 common shares at a price of CAD 0.18 per common share for proceeds of CAD 2,998,000 on August 22, 2023. The common shares issued pursuant are subject to a statutory hold period of four months. Helix BioPharma Corp. announces that it has closed the first tranche of private placement financing for gross proceeds of CAD 2,998,000.
공시 • Aug 23Helix BioPharma Corp. Announces Executive ChangesHelix BioPharma Corp. announced appointment of Mr. Janusz Grabski to the board of directors of the Company with an immediate effect. Mr. Grabski is a lawyer specialized in corporate law and real estate law with over twenty years of experience. Mr. Grabski is based in Warsaw, Poland. Alongside the appointment, the Company also announced resignation of Mr. Christopher Maciejewski from the board of directors of the Company due to personal reasons.
공시 • Nov 18Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023.